| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Principal Accounting Officer
1 company
Dunn Edmund serves as a Principal Accounting Officer at GLUE. Across recent SEC filings that breaks down to 0 buys and 7 sells. Those positions are worth an estimated $405K at current prices.
Historically, Dunn Edmund's trades have earned a below-average insider score of 20/100 across 4 rated trades. Over a 12-month horizon, 0.0% of those trades were profitable, with an average 12-month return of -51.0%.
The biggest single holding is GLUE (~$405K) as Principal Accounting Officer. The recent filings there lean toward selling, a net 31,757 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 4, 2026 | GLUE Monte Rosa Therapeutics, Inc. | Principal Accounting Officer | Sell | 139 | $17.96 | $2,496.44 | -0.6% | -4.7% | - | |
| Mar 2, 2026 | GLUE Monte Rosa Therapeutics, Inc. | Principal Accounting Officer | Sale+OE | 25,700 | $18.09 | $464,886.15 | -53.1% | +6.3% | - | |
| Jan 5, 2026 | GLUE Monte Rosa Therapeutics, Inc. | Principal Accounting Officer | Sell | 1,039 | $15.17 | $15,761.63 | -4.4% | +17.6% | - | |
| Jun 3, 2025 | GLUE Monte Rosa Therapeutics, Inc. | Principal Accounting Officer | Sell | 2,062 | $4.45 | $9,174.46 | -8.0% | +6.0% | +323.9% | |
| Jul 5, 2024 | GLUE Monte Rosa Therapeutics, Inc. | Principal Accounting Officer | Sell | 1,610 | $3.83 | $6,166.46 | -10.4% | +40.4% | +36.5% | |
| Jun 3, 2024 | GLUE Monte Rosa Therapeutics, Inc. | Principal Accounting Officer | Sell | 1,207 | $4.04 | $4,875.80 | -7.2% | +46.2% | +16.6% |